Beyond Air Inc (XAIR)

Currency in USD
5.420
-0.090(-1.63%)
Closed·
5.4200.000(0.00%)
·
Earnings results expected in 6 days
XAIR is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.3455.550
52 wk Range
5.10095.600
Key Statistics
Prev. Close
5.51
Open
5.54
Day's Range
5.345-5.55
52 wk Range
5.1-95.6
Volume
13.85K
Average Volume (3m)
15.76K
1-Year Change
-90.906%
Book Value / Share
11.64
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
XAIR Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
160.000
Upside
+2,852.03%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Beyond Air Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 160.000
(+2,852.03% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
BTIG
Hold---MaintainMar 26, 2026
Jones Trading
Buy2.00-63.10%6.00MaintainFeb 19, 2026
Rodman & Renshaw
Buy5.00-7.75%-New CoverageJan 20, 2026
Jones Trading
Buy6.00+10.70%12.00MaintainNov 11, 2025
Piper Sandler
Buy5.00-7.75%20.00MaintainAug 13, 2025

Beyond Air Inc SWOT Analysis


Innovative NO Delivery
Beyond Air's LungFit PH system generates nitric oxide from room air, potentially disrupting the $700 million global market for NO delivery systems
Financial Hurdles
Explore Beyond Air's strategy to overcome significant cash burn and reach cash flow breakeven by fiscal year 2027, despite lowered revenue projections
Market Expansion Plans
Learn about Beyond Air's efforts to expand LungFit PH's approved uses, including a pending FDA decision for cardiac surgeries and pursuit of CE mark in Europe
Competitive Landscape
Delve into Beyond Air's positioning against dominant players like Mallinckrodt, with analyst price target at $2.00 amid market challenges and opportunities
Read full SWOT analysis

Beyond Air Inc Earnings Call Summary for Q4/2026

  • Beyond Air reported fiscal 2026 revenue of $7.7M, up 107% YoY, with gross profit turning positive at $300K vs. $1.7M loss prior year.
  • Net loss narrowed to $33.2M from $46.6M; cash burn fell 56% to $19.1M as R&D and SG&A expenses declined 39% and 27% respectively.
  • Management forecasts calendar 2026 revenue of ~$8M and 2027 revenue of $16M-$18M, with half expected from Gen 2 LungFit PH system.
  • Gen 2 system under FDA review for potential H2 2026 approval could expand U.S. addressable market from $100M to $400M, global to $1B+.
  • Shares fell 9.85% to $0.43 despite strong results; risks include FDA approval uncertainty, limited cash of $17.3M vs. $21.6M debt.
Last Updated: 06/26/2026, 08:40 PM
Read Full Transcript

Earnings

Latest Release
Jun 26, 2026
EPS / Forecast
-15.40 / -1.50
Revenue / Forecast
1.91M / 5.47M
EPS Revisions
Last 90 days

XAIR Income Statement

Compare XAIR to Peers and Sector

Metrics to compare
XAIR
Peers
Sector
Relationship
P/E Ratio
−0.1x−2.0x−0.3x
PEG Ratio
0.00−0.060.00
Price/Book
0.6x2.5x2.6x
Price / LTM Sales
0.5x2.3x3.0x
Upside (Analyst Target)
-44.4%56.6%
Fair Value Upside
Unlock9.9%10.2%Unlock

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company. It operates through Beyond Air, Beyond Cancer, and NeuroNos segments. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO to treat viral lung infections, such as viral community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM). In addition, the company develops ultra-high concentration NO (UNO) that is in Phase 1 clinical trial to treat solid tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
11.48K1.59%63.25K
Other Institutional Investors
81.30K11.28%447.94K
Public Companies & Retail Investors
627.76K87.12%3.46M
Total
720.53K100.00%3.97M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Balyasny Asset Management L.P.3.22%23,208128
Atlas Diversified Master Fund, Ltd.3.22%23,208128

People Also Watch

20.430
UMAC
+18.37%
4.185
RXT
+10.71%
6.2700
ASTC
+0.97%
4.5200
MNTS
+8.65%
1.0300
HUBC
+0.98%

FAQ

What Is the Beyond Air (XAIR) Stock Price Today?

The Beyond Air stock price today is 5.420 USD.

What Stock Exchange Does Beyond Air Trade On?

Beyond Air is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Beyond Air?

The stock symbol for Beyond Air is "XAIR."

What Is the Beyond Air Market Cap?

As of today, Beyond Air market cap is 3.970M USD.

What Is Beyond Air's Earnings Per Share (TTM)?

The Beyond Air EPS (TTM) is -80.109.

When Is the Next Beyond Air Earnings Date?

Beyond Air will release its next earnings report on Aug 06, 2026.

From a Technical Analysis Perspective, Is XAIR a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Beyond Air Stock Split?

Beyond Air has split 3 times.

How Many Employees Does Beyond Air Have?

Beyond Air has 54 employees.

What is the current trading status of Beyond Air (XAIR)?

As of Jul 31, 2026, Beyond Air (XAIR) is trading at a price of 5.420 USD, with a previous close of 5.510 USD. The stock has fluctuated within a day range of 5.345 USD to 5.550 USD, while its 52-week range spans from 5.100 USD to 95.600 USD.

What Is Beyond Air (XAIR) Price Target According to Analysts?

The average 12-month price target for Beyond Air is 160.000 USD, with a high estimate of 280 USD and a low estimate of 40 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +2,852.03% Upside potential.

What Is the XAIR Premarket Price?

XAIR's last pre-market stock price is 5.550 USD. The pre-market share volume is 4,740.000, and the stock has decreased by 0.040, or 0.730%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.